FDA Accepts Supplemental NDA for QDOLO by Rosemont
The FDA has accepted a supplemental NDA for QDOLO, a tramadol hydrochloride formulation, submitted by Rosemont.
Asset / Drug
Drug and asset intelligence for Rosemont with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.